With an MD & PhD (biochemistry) from the University of Chicago, boards in Oncology, and Clinical Pharmacology, and as a pharma & biotech safety executive and faculty at Northwestern University Medical School, Dr. Fletcher provides expert advice in Pharmacovigilance, Safety Strategy, Oncology and Phase 1 Studies.

An oncologist with over 25 years experience in development and pharmacovigilance of oncology, neurology, gastroenterology, dermatology and obesity medicines, Peg is expert in evaluating safety data and balancing corporate obligations with patient safety.

With over 35 years of experience as a quality and compliance professional supporting global drug development and Pharmacovigilance activities, Beverley brings a wealth of knowledge to MedAssessment. She is a key expert for large pharma, start-up and established biotechnology companies, as well as academic medical research centers supporting the development and maintenance of compliant processes to support new chemical entities, biological products, marketed products, and medical devices.

Having such an impressive knowledge base and a unique skill set, Beverly provides expertise on establishing or improving quality management systems, preparation for, and responses to, regulatory authority inspections, as well as management of quality issues.

With over 16 years of clinical, academic, and leadership experience in health care, Dr Panik has served as Vice President for a $16 million dollar ONC HIT grant, a Hospital Medical Director and Chief of Staff, and a medical device Advisory Board member. 

Brian is also a Health Information Technology expert, a published Professor, and a Board-Certified Emergency Physician. With extensive clinical experience and over two years of industry experience, Brian has expertise in safety evaluation, signal detection, and aggregate reporting for Phase 1-3 studies, and also has significant medical device experience.

Dr. Panik is Lead Safety Physician for global studies in oncology and neuro-psychiatry products. He provides medical review of periodic and expedited cases including Analysis of Similar Events, literature review, database reconciliation, analysis of Safety Review Committee and aggregate data, as well as DSUR composition. He is also involved with business development, recruitment, and industry outreach for MedAssessment.

With an MD & PhD (biochemistry) from the University of Chicago, boards in Oncology, and Clinical Pharmacology, and as a pharma & biotech safety executive and faculty at Northwestern University Medical School, Dr. Fletcher provides expert advice in Pharmacovigilance, Safety Strategy, Oncology and Phase 1 Studies.

An oncologist with over 25 years experience in development and pharmacovigilance of oncology, neurology, gastroenterology, dermatology and obesity medicines, Peg is expert in evaluating safety data and balancing corporate obligations with patient safety.

Elizabeth has over 25 years of health and pharma experience, including 10 years in pharmacovigilance from both the sponsor industry and CRO perspectives, as well as 16 years as a Certified Principal Investigator (CPI) and medical director at a Phase 1-3 study unit. Elizabeth, now retired, is a family medicine physician with extensive women’s health experience in global settings.

Prior to joining the MedAssessment Board of Directors, Dr. Bianchi was Senior Director of Medical consulting at MedAssessment. As such, Elizabeth provides in-depth internal knowledge, executive management skills and broad industry perspective from her experiences at large pharma and start-up biotech companies in a wide variety of therapeutic areas with diverse project needs.

As CTO of Overhaul, Inc., Andy brings to the MedAssessment Board his extensive experience in strategy, growth and entrepreneurial problem-solving as companies move from start-up to growth-stage. 

Among Andy’s contributions to MedAssessment are agility and resilience lessons learned from other verticals, such as managing General Motors’ automotive plant circuit design, High-Tech logic design at AMD, High-Tech validation & programming at Intel, and as CEO and Co-Founder of Local Plant Source.